{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-133784","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.711385+00:00","generated_at":"2026-06-02T09:46:03.838935+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Karyopharm Q1 total revenue $33.1M, net loss $0.32/share; extends debt maturities to 2028/2029","bullets":["Q1 2024 total revenue $33.1M (vs $38.7M Q1 2023); U.S. XPOVIO net product revenue $26.0M (vs $28.3M Q1 2023).","Net loss $37.4M ($0.32 per share) vs $34.1M ($0.30 per share) in Q1 2023; R&D expenses $35.4M, SG&A $29.5M.","Reaffirms FY2024 guidance: total revenue $140-160M; XPOVIO net product revenue $100-120M; R&D+SG&A $260-280M.","Completed refinancing: extended majority of debt maturities to 2028/2029 and amended HCRx royalty, reducing royalty rate from 12.5% to 7.0%.","Cash, equivalents, restricted cash and investments $149.3M as of March 31, 2024; cash runway expected into end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-133784","json":"https://secwatch.observer/filing/0001193125-24-133784.json","markdown":"https://secwatch.observer/filing/0001193125-24-133784.md","text":"https://secwatch.observer/filing/0001193125-24-133784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524133784/0001193125-24-133784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524133784/d809399d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:46:03.838935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42408ca629e8249b21353dfa5e8860e275022969","claim":"Karyopharm Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $33.1 million. Guidance reaffirmed.","evidence_excerpt":"Readouts and Potential Approvals from the Company’s Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth – – Achieves First Quarter 2024 Total Revenue of $33.1 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $26.0 Million – – Reaffirms Full Year 2024 Total Revenue Guidance of $140.0 Million to $160.0 Million, Including U.S. XPOVIO","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524133784/0001193125-24-133784-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$33.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}